To learn more about liver research, please contact us at 504-988-1346.
In order to understand and treat liver disease, research is essential. The research team of Tulane's Section of Gastroenterology and Hepatology contributes to and participates in cutting edge research and clinical trials for the treatment of many GI and liver diseases.
The volunteers who participate in these clinical trials are key in the discovery of effective, new treatments. Our research team provides individualized, compassionate care and attention to all of our volunteers.
We are currently recruiting volunteers to participate in research for the following liver diseases and conditions:
Salix RNLC3131: A randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of Rifaximin soluble solid dispersion (SSD) tablets for the delay of encephalopathy decompensation in cirrhosis (PI: Dr. Fredric Regenstein) NCT05071716
Nearly half of people living with cirrhosis get hepatic encephalopathy (HE). HE is a complication of cirrhosis that can cause symptoms like:
- Confusion and personality changes
- Loss of small hand movements
- Tremors in hands and arms
- Sleep problems
The RNLC3131 Study is looking to see if a study medicine, rifaximin, can safely delay or prevent HE in adults with advanced liver cirrhosis. You may be eligible to participate if you are between the ages of 18 and 85 and have been diagnosed with liver cirrhosis.
PBC CymaBay CB8025-32251: "IDEAL" A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3
study Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase Levels in
Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to
Ursodeoxycholic Acid (UDCA)
The purpose of this clinical research study is to determine if seladelpar, an investigational drug, is effective at normalizing disease markers in subjects with PBC who are currently on UDCA (URSO) treatment or are intolerant to UDCA (URSO). Additionally, the study will test seladelpar's ability to relieve itching in PBC patients who qualify for the study and experience moderate to severe itch.
You may qualify for the study if:
- You are 18 - 75 years of age
- You have a confirmed diagnosis of PBC
- You have taken UDCA (URSO) for the 12 months prior to screening OR have had an incomplete or intolerant response 3 months prior to screening.
CymaBay CB8025-41837: "AFFIRM" A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Doctors usually prescribe UDCA (URSO) to help manage PBC, but it works better for some people than for others. This study will assess the effect of seladelpar on clinical outcomes, whether or not you are currently on UDCA (URSO).
You may qualify for this study if:
- You are 18 - 75 years of age
- You have been diagnosed with PBC
- You have a diagnosis of compensated cirrhosis with a Child-Pugh Score of A or B
If you are interested in learning more about our current clinical research trials, please contact us at 504-988-1346.
